Skin conditions (dermatitis, eczema, psoriasis) Board decisions

The appeals for an initial compensable rating for pseudofolliculitis barbae and service connection for residuals of tonsil removal have been withdrawn by the Veteran's attorney.

The Board remands the claims for service connection for a skin disorder, basal cell carcinoma of the left breast, and menorrhagia to correct duty to assist errors.

The Board denied service connection for bilateral hearing loss, a higher rating for migraine headaches, and a compensable rating for tinea corporis of the left elbow.

The Board granted a separate 60 percent rating for venous disease in the left lower extremity and a separate 40 percent rating for venous disease in the right lower extremity, but denied an initial rating in excess of 10 percent for statis dermatitis.

The Board remands the claims for further development, including obtaining a complete set of service treatment records and scheduling additional VA examinations.

The Board remands the claims for an initial compensable rating for seborrheic dermatitis, service connection for hypertension, and service connection for dry eyes to obtain additional evidence.

The Board denied service connection for benign prostatic hyperplasia and overflow incontinence, exhaustion, and dermatitis as the evidence did not show a causal relationship between these conditions and the Veteran's active-duty service, including exposure to contaminated water at Camp Lejeune.

The Board denied service connection for bilateral hearing loss, obstructive sleep apnea, posttraumatic stress disorder (PTSD), and right and left knee disabilities. However, the claim for an earlier effective date of December 30, 2022, for pseudofolliculitis barbae with dermatitis was granted.

The Board denied a compensable rating for vitamin deficiency and a disability rating in excess of 30 percent for pseudofolliculitis barbae (PFB) based on the evidence of record.

The Board remands the claims for a rating in excess of 70 percent for PTSD with TBI, a rating in excess of 10 percent for contact dermatitis, and whether the reduction from 30 percent to zero percent for migraine headaches was proper. The claim for TDIU is also remanded.

The Board granted annual clothing allowances for the 2022 calendar year for a back brace and betamethasone topical medication due to their respective impacts on the Veteran's clothing.

The Veteran withdrew his appeals for service connection and increased evaluations, resulting in the dismissal of all issues.

The Board granted a separate 10 percent disability rating for acne but denied compensable ratings for seborrheic keratosis with sebaceous cysts and posterior trunk scars.

The Board denied service connection for bilateral hearing loss, anxiety, bilateral tinea pedis, left knee condition, right knee condition, bilateral pes planus, low back strain, migraines, and non-specific respiratory condition as there was no evidence of a current disability at any time during the pendency of the appeal.

The Board granted a 20 percent rating for the right great toe injury and denied an initial rating in excess of 10 percent for dermatitis/eczema, as well as service connection for disability associated with high cholesterol.

The Board granted service connection for left foot pes planus, right foot pes planus, left foot plantar fasciitis, right foot plantar fasciitis, left foot tinea pedis, right foot tinea pedis, and bilateral tinnitus. The claims for major depressive disorder, anxiety disorder, and lumbar strain were remanded.

The Veteran's appeal for an initial rating in excess of 10 percent for onychomycosis of the bilateral feet and hands and pseudofolliculitis barbae was dismissed as he withdrew his claim.

The Board denied service connection for right knee joint osteoarthritis and chondromalacia, finding no evidence of a chronic condition in service or within the applicable presumptive period. The claim was also denied based on a lack of medical nexus between the current disability and an in-service injury.

The Board granted an earlier effective date of July 30, 2023 for the increased rating of allergic rhinitis and denied it for the skin disability and facial scars.

The Board granted an effective date of June 19, 2018 for a 60 percent rating for tinea versicolor and denied an earlier effective date for DEA benefits.